PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY

Autor:	L. Cirillo, M. Savoia, N. Despiégel, B. Haffemayer, A. D'Arpino, A. Giannopoulou, I. Gaikwad
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Trastuzumab business.industry Health Policy Internal medicine Perspective (graphical) Public Health Environmental and Occupational Health medicine Cost analysis Biosimilar business medicine.drug
Zdroj:	Value in Health. 22:S449
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.269
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b4dae3993cda95fe29283924d2d20ae0 https://doi.org/10.1016/j.jval.2019.09.269 Zobrazit plný text záznamu Full Text from ScienceDirect